Lyell Immunopharma
LYEL
LYEL
106 hedge funds and large institutions have $180M invested in Lyell Immunopharma in 2023 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 46 increasing their positions, 21 reducing their positions, and 9 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.01% less ownership
Funds ownership: 2.45% → 2.44% (-0.01%)
54% less capital invested
Capital invested by funds: $389M → $180M (-$209M)
Holders
106
Holding in Top 10
3
Calls
$15K
Puts
$4K
Top Buyers
| 1 | +$1.04M | |
| 2 | +$940K | |
| 3 | +$712K | |
| 4 |
BlackRock
New York
|
+$498K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$413K |
Top Sellers
| 1 | -$2.17M | |
| 2 | -$1.94M | |
| 3 | -$1.35M | |
| 4 |
Goldman Sachs
New York
|
-$174K |
| 5 |
Morgan Stanley
New York
|
-$142K |